Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study

6533b82afe1ef96bd128b7b8

RESEARCH PRODUCT

Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study

Giovanni Iolascon Vincenzo Falco Alessandro De Sire Alessandro De Sire Dalila Scaturro Fabio Vitagliani Daniele Cuntrera Pietro Terrana Giulia Letizia Mauro Claudio Curci

subject

Osteoporosis risk of fracture 0302 clinical medicine Retrospective Studie Bone Density Orthopedics and Sports Medicine 030212 general & internal medicine Aromatase Osteoporosis Postmenopausal biology Bone Density Conservation Agents Aromatase Inhibitors Settore MED/34 - Medicina Fisica E Riabilitativa Medical record Rehabilitation Middle Aged medicine.anatomical_structure Denosumab 030220 oncology & carcinogenesis Osteoporosis risk of fractures breast cancer denosumab bone health Female Denosumab Case-Control Studie Breast Neoplasm Human medicine.drug medicine.medical_specialty Bone Density Conservation Agent Physical Therapy Sports Therapy and Rehabilitation Breast Neoplasms Bone health 03 medical and health sciences breast cancer Breast cancer Internal medicine medicine Aromatase Inhibitor Humans bone health Femoral neck Aged Retrospective Studies risk of fractures business.industry Osteoporosi Retrospective cohort study medicine.disease Case-Control Studies biology.protein business Osteoporotic Fractures

description

BACKGROUND: Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women. Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined. OBJECTIVE: To evaluate the effects of early treatment with Denosumab (⩽ 12 months after starting AIs) compared to a delayed treatment in BC women. METHODS: In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with AIs therapy; they were divided as: study group (starting Denosumab ⩽ 12 months after AIs) and control group (> 12 months). At the baseline (T0) and at 18 months (T1), we evaluated the lumbar spine (LS) Tscore and femoral neck (FN) Tscore. Furthermore, at T1 we assessed the incident fragility fractures. RESULTS: Fifty-nine BC survivors (mean age: 61.5 ± 11.5 years) were included: 28 with Early Denosumab and 31 with Late Denosumab. At T1, the study group did not show any incident hip or vertebral fragility fracture, whereas the Late Denosumab group showed 2 incident hip fractures (6.5%) and 4 (12.9%) vertebral fragility fractures. Early Denosumab showed a significant positive effect on both LS (p= 0.044) and FN (p= 0.024) Tscore variations. CONCLUSION: Taken together, our findings suggest that an early start of Denosumab might be considered for the osteoporosis management in BC women undergoing AIs.

year	journal	country	edition	language
2021-05-12

https://iris.unipa.it/handle/10447/512877